CN113402612A - 靶向cd19和cd20的联合嵌合抗原受体及其应用 - Google Patents

靶向cd19和cd20的联合嵌合抗原受体及其应用 Download PDF

Info

Publication number
CN113402612A
CN113402612A CN202010188038.1A CN202010188038A CN113402612A CN 113402612 A CN113402612 A CN 113402612A CN 202010188038 A CN202010188038 A CN 202010188038A CN 113402612 A CN113402612 A CN 113402612A
Authority
CN
China
Prior art keywords
ser
gly
leu
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010188038.1A
Other languages
English (en)
Chinese (zh)
Inventor
姚意弘
李延峰
魏雨恬
朱恃贵
姚昕
黄家琪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xibiman Biotechnology Group
Original Assignee
Cellular Biomedicine Group HK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Biomedicine Group HK Ltd filed Critical Cellular Biomedicine Group HK Ltd
Priority to CN202010188038.1A priority Critical patent/CN113402612A/zh
Priority to US16/877,069 priority patent/US11207349B2/en
Priority to JP2022506548A priority patent/JP7624967B2/ja
Priority to US17/911,502 priority patent/US20230104705A1/en
Priority to UAA202203670A priority patent/UA129998C2/uk
Priority to CA3169235A priority patent/CA3169235A1/en
Priority to PCT/CN2020/109645 priority patent/WO2021184673A1/en
Priority to NZ793365A priority patent/NZ793365A/en
Priority to EP25182520.4A priority patent/EP4631525A3/en
Priority to PCT/US2021/022779 priority patent/WO2021188681A1/en
Priority to DK21772208.1T priority patent/DK3989986T3/da
Priority to JP2022506726A priority patent/JP7212222B2/ja
Priority to IL317912A priority patent/IL317912A/en
Priority to LTEPPCT/US2021/022779T priority patent/LT3989986T/lt
Priority to RS20250825A priority patent/RS67131B1/sr
Priority to KR1020237011866A priority patent/KR20230053705A/ko
Priority to US17/911,524 priority patent/US20230212255A1/en
Priority to PT217722081T priority patent/PT3989986T/pt
Priority to PE2022002042A priority patent/PE20231643A1/es
Priority to MX2022011554A priority patent/MX2022011554A/es
Priority to CA3169239A priority patent/CA3169239A1/en
Priority to IL296473A priority patent/IL296473B2/en
Priority to HRP20251006TT priority patent/HRP20251006T1/hr
Priority to PL21772208.1T priority patent/PL3989986T3/pl
Priority to AU2021238330A priority patent/AU2021238330B2/en
Priority to PH1/2022/552463A priority patent/PH12022552463A1/en
Priority to KR1020227035401A priority patent/KR102520550B1/ko
Priority to ES21772208T priority patent/ES3039539T3/es
Priority to EP21772208.1A priority patent/EP3989986B1/en
Priority to BR112022018677A priority patent/BR112022018677A2/pt
Priority to SI202130340T priority patent/SI3989986T1/sl
Priority to CN202180035520.4A priority patent/CN115955974A/zh
Priority to FIEP21772208.1T priority patent/FI3989986T3/fi
Priority to CR20220507A priority patent/CR20220507A/es
Priority to SM20250287T priority patent/SMT202500287T1/it
Priority to US17/475,766 priority patent/US11439665B2/en
Publication of CN113402612A publication Critical patent/CN113402612A/zh
Priority to US17/721,647 priority patent/US12448432B2/en
Priority to US17/750,658 priority patent/US11633430B2/en
Priority to CL2022002522A priority patent/CL2022002522A1/es
Priority to DO2022000195A priority patent/DOP2022000195A/es
Priority to CONC2022/0014259A priority patent/CO2022014259A2/es
Priority to ECSENADI202279948A priority patent/ECSP22079948A/es
Priority to JP2022202035A priority patent/JP7624961B2/ja
Priority to AU2023200268A priority patent/AU2023200268A1/en
Priority to US18/183,681 priority patent/US20240139243A1/en
Priority to JP2025008195A priority patent/JP2025066770A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202010188038.1A 2020-03-17 2020-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用 Pending CN113402612A (zh)

Priority Applications (46)

Application Number Priority Date Filing Date Title
CN202010188038.1A CN113402612A (zh) 2020-03-17 2020-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用
US16/877,069 US11207349B2 (en) 2020-03-17 2020-05-18 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
JP2022506548A JP7624967B2 (ja) 2020-03-17 2020-08-17 Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用
US17/911,502 US20230104705A1 (en) 2020-03-17 2020-08-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
UAA202203670A UA129998C2 (uk) 2020-03-17 2020-08-17 Комбінований химерний антигенний рецептор, що націлює cd19 і cd20, та його застосування
CA3169235A CA3169235A1 (en) 2020-03-17 2020-08-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
PCT/CN2020/109645 WO2021184673A1 (en) 2020-03-17 2020-08-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
PL21772208.1T PL3989986T3 (pl) 2020-03-17 2021-03-17 Połączony chimeryczny receptor antygenowy ukierunkowany na cd19 i cd20 i jego zastosowania
EP21772208.1A EP3989986B1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
PCT/US2021/022779 WO2021188681A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
DK21772208.1T DK3989986T3 (da) 2020-03-17 2021-03-17 Kombineret kimær antigenreceptor målrettet mod cd19 og cd20 og anvendelser deraf
JP2022506726A JP7212222B2 (ja) 2020-03-17 2021-03-17 Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用
IL317912A IL317912A (en) 2020-03-17 2021-03-17 A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
LTEPPCT/US2021/022779T LT3989986T (lt) 2020-03-17 2021-03-17 Suderintas chimerinis antigenų receptorius, skirtas cd19 ir cd20, ir jo taikymas
RS20250825A RS67131B1 (sr) 2020-03-17 2021-03-17 Kombinovani himerni antigenski receptor usmeren na cd19 i cd20 i njegove primene
KR1020237011866A KR20230053705A (ko) 2020-03-17 2021-03-17 Cd19 및 cd20을 표적화하는 조합된 키메라 항원 수용체 및 그의 적용
US17/911,524 US20230212255A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
PT217722081T PT3989986T (pt) 2020-03-17 2021-03-17 Recetor de antigénio quimérico combinado dirigido a cd19 e cd20 e aplicações deste
PE2022002042A PE20231643A1 (es) 2020-03-17 2021-03-17 Receptor de antigeno quimerico combinado dirigido a cd19 y cd20 y aplicaciones de los mismos
MX2022011554A MX2022011554A (es) 2020-03-17 2021-03-17 Receptor de antigeno quimerico combinado dirigido a cd19 y cd20 y sus aplicaciones.
CA3169239A CA3169239A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
IL296473A IL296473B2 (en) 2020-03-17 2021-03-17 A combined chimeric antigen receptor targeting CD19 and CD20 and its applications
HRP20251006TT HRP20251006T1 (hr) 2020-03-17 2021-03-17 Kombinirani kimerni antigenski receptor usmjeren na cd19 i cd20 i njegove primjene
NZ793365A NZ793365A (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
AU2021238330A AU2021238330B2 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting CD19 and CD20 and applications thereof
PH1/2022/552463A PH12022552463A1 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
KR1020227035401A KR102520550B1 (ko) 2020-03-17 2021-03-17 Cd19 및 cd20을 표적화하는 조합된 키메라 항원 수용체 및 그의 적용
ES21772208T ES3039539T3 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
EP25182520.4A EP4631525A3 (en) 2020-03-17 2021-03-17 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
BR112022018677A BR112022018677A2 (pt) 2020-03-17 2021-03-17 Receptor de antígeno quimérico combinado que alveja cd19 e cd20 e aplicação do mesmo
SI202130340T SI3989986T1 (sl) 2020-03-17 2021-03-17 Kombinirani kimerski receptorji antigena, usmerjeni v cd19 in cd20, in njihova uporaba
CN202180035520.4A CN115955974A (zh) 2020-03-17 2021-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用
FIEP21772208.1T FI3989986T3 (fi) 2020-03-17 2021-03-17 Yhdistetty kimeerinen antigeenireseptori, joka kohdistuu cd19:ään ja cd20:een, ja sen käyttötapoja
CR20220507A CR20220507A (es) 2020-03-17 2021-03-17 Receptor de antígeno quimérico combinado dirigido a cd19 y cd20 y sus aplicaciones
SM20250287T SMT202500287T1 (it) 2020-03-17 2021-03-17 Recettore dell'antigene chimerico combinato che mira cd19 e cd20 e applicazioni di esso
US17/475,766 US11439665B2 (en) 2020-03-17 2021-09-15 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US17/721,647 US12448432B2 (en) 2020-03-17 2022-04-15 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
US17/750,658 US11633430B2 (en) 2020-03-17 2022-05-23 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
CL2022002522A CL2022002522A1 (es) 2020-03-17 2022-09-15 Receptor de antígeno quimérico combinado dirigido a cd19 y cd20 y sus aplicaciones.
DO2022000195A DOP2022000195A (es) 2020-03-17 2022-09-20 Receptor de antígeno quimérico combinado dirigido a cd19 y cd20 y sus aplicaciones
CONC2022/0014259A CO2022014259A2 (es) 2020-03-17 2022-10-05 Receptor de antígeno quimérico combinado dirigido a cd19 y cd20 y sus aplicaciones
ECSENADI202279948A ECSP22079948A (es) 2020-03-17 2022-10-13 Receptor de antígeno quimérico combinado dirigido a cd 19 y cd20 y sus aplicaciones
JP2022202035A JP7624961B2 (ja) 2020-03-17 2022-12-19 Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用
AU2023200268A AU2023200268A1 (en) 2020-03-17 2023-01-19 Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
US18/183,681 US20240139243A1 (en) 2020-03-17 2023-03-14 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
JP2025008195A JP2025066770A (ja) 2020-03-17 2025-01-21 Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010188038.1A CN113402612A (zh) 2020-03-17 2020-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用

Publications (1)

Publication Number Publication Date
CN113402612A true CN113402612A (zh) 2021-09-17

Family

ID=77677447

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010188038.1A Pending CN113402612A (zh) 2020-03-17 2020-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN202180035520.4A Pending CN115955974A (zh) 2020-03-17 2021-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180035520.4A Pending CN115955974A (zh) 2020-03-17 2021-03-17 靶向cd19和cd20的联合嵌合抗原受体及其应用

Country Status (30)

Country Link
US (5) US11207349B2 (enExample)
EP (2) EP3989986B1 (enExample)
JP (4) JP7624967B2 (enExample)
KR (2) KR102520550B1 (enExample)
CN (2) CN113402612A (enExample)
AU (2) AU2021238330B2 (enExample)
BR (1) BR112022018677A2 (enExample)
CA (2) CA3169235A1 (enExample)
CL (1) CL2022002522A1 (enExample)
CO (1) CO2022014259A2 (enExample)
CR (1) CR20220507A (enExample)
DK (1) DK3989986T3 (enExample)
DO (1) DOP2022000195A (enExample)
EC (1) ECSP22079948A (enExample)
ES (1) ES3039539T3 (enExample)
FI (1) FI3989986T3 (enExample)
HR (1) HRP20251006T1 (enExample)
IL (2) IL296473B2 (enExample)
LT (1) LT3989986T (enExample)
MX (1) MX2022011554A (enExample)
NZ (1) NZ793365A (enExample)
PE (1) PE20231643A1 (enExample)
PH (1) PH12022552463A1 (enExample)
PL (1) PL3989986T3 (enExample)
PT (1) PT3989986T (enExample)
RS (1) RS67131B1 (enExample)
SI (1) SI3989986T1 (enExample)
SM (1) SMT202500287T1 (enExample)
UA (1) UA129998C2 (enExample)
WO (2) WO2021184673A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024240112A1 (zh) * 2023-05-19 2024-11-28 科济生物医药（上海）有限公司 免疫效应细胞及其应用
WO2025021113A1 (zh) * 2023-07-25 2025-01-30 上海药明巨诺生物医药研发有限公司 用于治疗与cd20相关的疾病的融合蛋白
WO2025030693A1 (zh) * 2023-08-08 2025-02-13 星尘生物科技(上海)有限公司 双特异性嵌合抗原受体及其应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
KR102739632B1 (ko) * 2022-02-09 2024-12-05 한림대학교 산학협력단 항-cd20 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2023208157A1 (zh) * 2022-04-29 2023-11-02 上海先博生物科技有限公司 靶向cd19的嵌合抗原受体及其应用
CN114990069B (zh) * 2022-05-17 2023-09-22 郑州大学第一附属医院 一种过表达slc43a2的嵌合抗原受体t细胞的制备方法和应用
EP4577571A1 (en) * 2022-08-26 2025-07-02 Lentigen Technology, Inc. Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
CN116514992B (zh) * 2022-11-07 2024-05-24 武汉波睿达生物科技有限公司 一种信号肽序列优化的靶向cd19的嵌合抗原受体及其应用
AU2024230609A1 (en) 2023-02-28 2025-09-04 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
CN120641113A (zh) 2023-03-31 2025-09-12 西比曼生物科技集团 靶向cd20和bcma的双特异性嵌合抗原受体
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107868791A (zh) * 2016-09-26 2018-04-03 李华顺 一种加强型Slit2 CAR‑T和CAR‑NK细胞制备方法和应用
CN107936120A (zh) * 2016-10-13 2018-04-20 上海赛比曼生物科技有限公司 Cd19靶向性的嵌合抗原受体及其制法和应用
CN108395482A (zh) * 2017-02-08 2018-08-14 西比曼生物科技（上海）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
CN108472346A (zh) * 2015-11-05 2018-08-31 朱诺治疗学股份有限公司 含有traf诱导结构域的嵌合受体及相关组合物和方法
CN108715616A (zh) * 2018-04-27 2018-10-30 上海恒润达生生物科技有限公司 靶向人源化间皮素的嵌合抗原受体方法和用途
CN109575143A (zh) * 2018-12-29 2019-04-05 博生吉医药科技(苏州)有限公司 双特异性cd20-cd19-car及其应用
CN110062768A (zh) * 2016-12-15 2019-07-26 美天旎生物技术有限公司 表达抗原结合受体和嵌合共刺激受体的免疫细胞
CN110845623A (zh) * 2019-10-11 2020-02-28 厦门大学 一种egfr特异性嵌合抗原受体及其应用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6074841A (en) 1996-08-19 2000-06-13 Millennium Biotherapeutics, Inc. Don-1 gene and polypeptides and uses therefor
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
KR20120125634A (ko) 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CA2656620C (en) 2006-07-04 2018-03-13 Genmab A/S Cd20 binding molecules for the treatment of copd
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2167130A2 (en) 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
AU2008282152B2 (en) 2007-07-31 2013-12-19 Regeneron Pharmaceuticals, Inc. Human antibodies to human CD20 and method of using thereof
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
WO2009052830A1 (en) 2007-10-22 2009-04-30 Genmab A/S Novel antibody therapies
CN101544694A (zh) 2008-03-28 2009-09-30 上海中信国健药业有限公司 抗cd20四价抗体、其制备方法和应用
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
EP2872170A4 (en) 2012-07-13 2016-06-22 Zymeworks Inc ASYMMETRIC BISPECIFIC HETERODIMERS WITH ANTI-CD3 CONSTRUCTS
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP2015092865A (ja) 2013-11-13 2015-05-18 国立大学法人名古屋大学 ヒト化抗ｃｄ２０キメラ抗原レセプター
MX386422B (es) * 2013-12-20 2025-03-18 Fred Hutchinson Cancer Center Moléculas efectoras químericas etiquetadas y receptores de las mismas.
ES2767423T3 (es) 2014-01-13 2020-06-17 Hope City Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3149044B1 (en) 2014-06-02 2020-10-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptors targeting cd-19
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
MX392487B (es) 2014-10-20 2025-03-21 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva.
KR102804498B1 (ko) 2014-12-03 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 방법 및 조성물
SI3240805T1 (sl) * 2014-12-15 2025-04-30 The Regents Of The University Of California Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20
WO2016097231A2 (en) 2014-12-17 2016-06-23 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
WO2016110576A1 (en) 2015-01-08 2016-07-14 Genmab A/S Bispecific antibodies against cd3 and cd20
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
KR20170110601A (ko) 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
US11248058B2 (en) 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
MA41613A (fr) 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
GB201506223D0 (en) 2015-04-13 2015-05-27 Ucl Business Plc Chimeric protein
WO2016168773A2 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016176651A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2016179319A1 (en) 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
CN108603170A (zh) 2015-06-12 2018-09-28 莱蒂恩技术公司 用工程改造的t细胞治疗癌症的方法
US10493139B2 (en) * 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
SG10201912734PA (en) 2015-08-05 2020-02-27 Yoo Young Pharm Co Ltd Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108135932A (zh) 2015-08-28 2018-06-08 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
CN108602872A (zh) 2015-10-30 2018-09-28 艾丽塔生物治疗剂公司 用于治疗癌症的组合物和方法
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
MX2018010415A (es) 2016-03-18 2018-11-29 Hutchinson Fred Cancer Res Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
CA3018253A1 (en) * 2016-03-31 2017-10-05 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
AU2017341047B2 (en) * 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
CN108250301A (zh) 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多靶点嵌合抗原受体
CN108276493B (zh) 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
AU2018225153A1 (en) * 2017-02-22 2019-09-19 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
KR20190133017A (ko) 2017-03-27 2019-11-29 에프. 호프만-라 로슈 아게 개선된 항원 결합 수용체 구성
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
US11434290B2 (en) 2017-06-08 2022-09-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with enhanced NFκB signaling
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
CN109423495A (zh) 2017-08-24 2019-03-05 上海恒润达生生物科技有限公司 一种双靶向嵌合抗原受体及其用途
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
US11905528B2 (en) 2017-10-12 2024-02-20 Icell Gene Therapeutics Inc. Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
TW201922256A (zh) * 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
US20220218745A1 (en) 2017-12-22 2022-07-14 2Seventy Bio, Inc. Multivalent chimeric antigen receptor
CN108315305B (zh) 2017-12-26 2020-11-06 沣潮医药科技（上海）有限公司 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用
CN109971725B (zh) 2017-12-28 2024-02-02 上海细胞治疗研究院 抗体修饰的嵌合抗原受体修饰t细胞及其用途
CN108285486A (zh) 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
CN108017717B (zh) 2018-01-24 2019-08-16 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
US20230183313A1 (en) 2018-02-11 2023-06-15 Jiangsu Hengrui Medicine Co., Ltd. Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
KR20210033941A (ko) 2018-04-28 2021-03-29 이뮤노테크 바이오팜 씨오., 엘티디. 개선된 t-세포 요법
CN110526983B (zh) 2018-05-24 2022-02-11 北京马力喏生物科技有限公司 改良型抗cd19 car-t细胞
WO2019232444A1 (en) 2018-05-31 2019-12-05 Washington University Chimeric antigen receptor t cells (car-t) for the treatment of cancer
CN110606893B (zh) 2018-06-15 2022-11-15 北昊干细胞与再生医学研究院有限公司 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
WO2020033273A1 (en) 2018-08-04 2020-02-13 AbCyte Therapeutics Inc. Multi-function and multi-targeting car system and methods for use thereof
JP2022501067A (ja) 2018-09-26 2022-01-06 上海恒潤達生生物科技有限公司Hrain Biotechnology Co., Ltd. Ｂｃｍａ及びｃｄ１９を標的とするキメラ抗原受容体、並びにその使用
SG11202103235PA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
CN109536455B (zh) 2018-12-11 2020-02-21 武汉波睿达生物科技有限公司 一种car-nk细胞及其制备方法和应用
CN113412117B (zh) * 2018-12-12 2025-03-04 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
CN113330038A (zh) 2019-01-22 2021-08-31 亘喜生物科技（上海）有限公司 Cd20组合靶向的工程化免疫细胞
JP7395200B2 (ja) 2019-03-25 2023-12-11 イミュンワーク インク． 金属結合モチーフを有する複合ポリペプチド及びそれを備える分子構築物
CN112390891B (zh) 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
US20230212255A1 (en) 2020-03-17 2023-07-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
US20230104705A1 (en) 2020-03-17 2023-04-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
CN112608387B (zh) 2020-12-21 2023-05-05 汤朝阳 Cd19和cd20双靶点嵌合抗原受体及其应用
US20240115605A1 (en) 2021-01-27 2024-04-11 Cellular Biomedicine Group, Inc. Chimeric antigen receptors targeting cd20

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472346A (zh) * 2015-11-05 2018-08-31 朱诺治疗学股份有限公司 含有traf诱导结构域的嵌合受体及相关组合物和方法
CN107868791A (zh) * 2016-09-26 2018-04-03 李华顺 一种加强型Slit2 CAR‑T和CAR‑NK细胞制备方法和应用
CN107936120A (zh) * 2016-10-13 2018-04-20 上海赛比曼生物科技有限公司 Cd19靶向性的嵌合抗原受体及其制法和应用
CN110062768A (zh) * 2016-12-15 2019-07-26 美天旎生物技术有限公司 表达抗原结合受体和嵌合共刺激受体的免疫细胞
CN108395482A (zh) * 2017-02-08 2018-08-14 西比曼生物科技（上海）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
CN108715616A (zh) * 2018-04-27 2018-10-30 上海恒润达生生物科技有限公司 靶向人源化间皮素的嵌合抗原受体方法和用途
CN109575143A (zh) * 2018-12-29 2019-04-05 博生吉医药科技(苏州)有限公司 双特异性cd20-cd19-car及其应用
CN110845623A (zh) * 2019-10-11 2020-02-28 厦门大学 一种egfr特异性嵌合抗原受体及其应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024240112A1 (zh) * 2023-05-19 2024-11-28 科济生物医药（上海）有限公司 免疫效应细胞及其应用
WO2025021113A1 (zh) * 2023-07-25 2025-01-30 上海药明巨诺生物医药研发有限公司 用于治疗与cd20相关的疾病的融合蛋白
WO2025030693A1 (zh) * 2023-08-08 2025-02-13 星尘生物科技(上海)有限公司 双特异性嵌合抗原受体及其应用

Also Published As

Publication number Publication date
ECSP22079948A (es) 2022-12-30
IL296473B1 (en) 2025-01-01
UA129998C2 (uk) 2025-10-08
PT3989986T (pt) 2025-09-08
JP2022536195A (ja) 2022-08-12
PL3989986T3 (pl) 2025-09-29
IL317912A (en) 2025-02-01
KR20230053705A (ko) 2023-04-21
EP3989986B1 (en) 2025-07-09
JP2025066770A (ja) 2025-04-23
SI3989986T1 (sl) 2025-10-30
AU2023200268A1 (en) 2023-02-16
CN115955974A (zh) 2023-04-11
CL2022002522A1 (es) 2023-04-21
LT3989986T (lt) 2025-09-10
IL296473B2 (en) 2025-05-01
DOP2022000195A (es) 2023-02-28
DK3989986T3 (da) 2025-08-18
HRP20251006T1 (hr) 2025-11-07
JP2023027314A (ja) 2023-03-01
US20220031752A1 (en) 2022-02-03
US20210290673A1 (en) 2021-09-23
PE20231643A1 (es) 2023-10-16
US11633430B2 (en) 2023-04-25
KR20220145411A (ko) 2022-10-28
WO2021184673A1 (en) 2021-09-23
FI3989986T3 (fi) 2025-08-15
EP4631525A2 (en) 2025-10-15
MX2022011554A (es) 2022-12-13
JP7624967B2 (ja) 2025-01-31
US11207349B2 (en) 2021-12-28
ES3039539T3 (en) 2025-10-22
WO2021188681A1 (en) 2021-09-23
CA3169235A1 (en) 2021-09-23
KR102520550B1 (ko) 2023-04-12
BR112022018677A2 (pt) 2023-02-23
SMT202500287T1 (it) 2025-11-10
PH12022552463A1 (en) 2024-01-03
NZ793365A (en) 2023-03-31
CR20220507A (es) 2022-11-22
AU2021238330B2 (en) 2023-02-23
US20220249568A1 (en) 2022-08-11
US11439665B2 (en) 2022-09-13
US12448432B2 (en) 2025-10-21
US20220288123A1 (en) 2022-09-15
EP4631525A3 (en) 2025-12-24
RS67131B1 (sr) 2025-09-30
JP7624961B2 (ja) 2025-01-31
JP2023518134A (ja) 2023-04-28
US20240139243A1 (en) 2024-05-02
IL296473A (en) 2022-11-01
AU2021238330A1 (en) 2022-11-17
CO2022014259A2 (es) 2022-10-31
JP7212222B2 (ja) 2023-01-25
EP3989986A4 (en) 2022-10-12
EP3989986A1 (en) 2022-05-04
CA3169239A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
US12448432B2 (en) Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
CN111051502B (zh) 通用型嵌合抗原受体t细胞制备技术
JP7664657B2 (ja) 二重特異性ｃｓ１－ｂｃｍａ ｃａｒ－ｔ細胞及びその適用
CN110950953A (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
CN109575143B (zh) 双特异性cd20-cd19-car及其应用
CN113087806A (zh) 靶向多种肿瘤的新型car-t细胞及其制备和方法
US20230104705A1 (en) Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
CN113651893B (zh) 联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
CN114763388B (zh) 靶向b7-h3的car-t细胞及其在急性髓系白血病治疗中的应用
CN109897114B (zh) 具有自杀基因开关的靶向cd47的工程化免疫细胞
CN116462770B (zh) Cd19的人源化抗体和一种表达双特异性嵌合抗原受体的car-t细胞及其应用
EP4151653A1 (en) Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof
CN110577932A (zh) 一种脐带血来源的嵌合抗原受体t细胞
CN114685683A (zh) 靶向gd2的car-t细胞及其制备和应用
CN119350497A (zh) 人源化抗cd19单链可变区片段及其用途
HK40087789A (en) Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20221024

Address after: Building 3, No. 85 Faraday Road, Pudong New Area (Shanghai) Pilot Free Trade Zone, Shanghai

Applicant after: SHANGHAI CELLULAR BIOPHARMACEUTICAL Group Ltd.

Address before: Room 417, 4 / F, tower 2, Lippo centre, 89 Queensway, Hong Kong, China

Applicant before: CELLULAR BIOMEDICINE GROUP HK Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231106

Address after: Maryland, USA

Applicant after: Xibiman Biotechnology Group

Address before: 201210 Building 3, No. 85 Faraday Road, Pudong New Area (Shanghai) Pilot Free Trade Zone, Shanghai

Applicant before: SHANGHAI CELLULAR BIOPHARMACEUTICAL Group Ltd.

TA01 Transfer of patent application right